160 related articles for article (PubMed ID: 37883734)
1. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J; Ferguson W; Kraveka JM; Bergendahl G; Clinch T; Lorenzi E; Berry D; Wada RK; Isakoff MS; Eslin DE; Brown VI; Roberts W; Zage P; Harrod VL; Mitchell DS; Hanson D; Saulnier Sholler GL
J Clin Oncol; 2024 Jan; 42(1):90-102. PubMed ID: 37883734
[TBL] [Abstract][Full Text] [Related]
2. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Lewis EC; Kraveka JM; Ferguson W; Eslin D; Brown VI; Bergendahl G; Roberts W; Wada RK; Oesterheld J; Mitchell D; Foley J; Zage P; Rawwas J; Rich M; Lorenzi E; Broglio K; Berry D; Saulnier Sholler GL
Int J Cancer; 2020 Dec; 147(11):3152-3159. PubMed ID: 32391579
[TBL] [Abstract][Full Text] [Related]
3. Maintenance DFMO Increases Survival in High Risk Neuroblastoma.
Sholler GLS; Ferguson W; Bergendahl G; Bond JP; Neville K; Eslin D; Brown V; Roberts W; Wada RK; Oesterheld J; Mitchell D; Foley J; Parikh NS; Eshun F; Zage P; Rawwas J; Sencer S; Pankiewicz D; Quinn M; Rich M; Junewick J; Kraveka JM
Sci Rep; 2018 Sep; 8(1):14445. PubMed ID: 30262852
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Kraveka JM; Lewis EC; Bergendahl G; Ferguson W; Oesterheld J; Kim E; Nagulapally AB; Dykema KJ; Brown VI; Roberts WD; Mitchell D; Eslin D; Hanson D; Isakoff MS; Wada RK; Harrod VL; Rawwas J; Hanna G; Hendricks WPD; Byron SA; Snuderl M; Serrano J; Trent JM; Saulnier Sholler GL
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1616. PubMed ID: 35355452
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
8. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Desai AV; Gilman AL; Ozkaynak MF; Naranjo A; London WB; Tenney SC; Diccianni M; Hank JA; Parisi MT; Shulkin BL; Smith M; Moscow JA; Shimada H; Matthay KK; Cohn SL; Maris JM; Bagatell R; Sondel PM; Park JR; Yu AL
J Clin Oncol; 2022 Dec; 40(35):4107-4118. PubMed ID: 35839426
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
[TBL] [Abstract][Full Text] [Related]
10. The optimal timing of surgical resection in high-risk neuroblastoma.
Rojas Y; Jaramillo S; Lyons K; Mahmood N; Wu MF; Liu H; Vasudevan SA; Guillerman RP; Louis CU; Russell HV; Nuchtern JG; Kim ES
J Pediatr Surg; 2016 Oct; 51(10):1665-9. PubMed ID: 27318861
[TBL] [Abstract][Full Text] [Related]
11. Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma.
Bona K; Li Y; Winestone LE; Getz KD; Huang YS; Fisher BT; Desai AV; Richardson T; Hall M; Naranjo A; Henderson TO; Aplenc R; Bagatell R
J Natl Cancer Inst; 2021 Mar; 113(3):282-291. PubMed ID: 33227816
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Erbe AK; Wang W; Carmichael L; Kim K; Mendonça EA; Song Y; Hess D; Reville PK; London WB; Naranjo A; Hank JA; Diccianni MB; Reisfeld RA; Gillies SD; Matthay KK; Cohn SL; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Gilman AL; Yu AL; Sondel PM
Clin Cancer Res; 2018 Jan; 24(1):189-196. PubMed ID: 28972044
[No Abstract] [Full Text] [Related]
16. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma.
Herd F; Basta NO; McNally RJQ; Tweddle DA
Eur J Cancer; 2019 Apr; 111():50-58. PubMed ID: 30822684
[TBL] [Abstract][Full Text] [Related]
17. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
19. DFMO inhibition of neuroblastoma tumorigenesis.
Gandra D; Mulama DH; Foureau DM; McKinney KQ; Kim E; Smith K; Haw J; Nagulapally A; Saulnier Sholler GL
Cancer Med; 2024 May; 13(9):e7207. PubMed ID: 38686627
[TBL] [Abstract][Full Text] [Related]
20. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Enk H; Tytgat GA
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012442. PubMed ID: 31016728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]